Literature DB >> 32866512

Germline HSD3B1 Genetics and Prostate Cancer Outcomes.

Lewis Thomas1, Nima Sharifi2.   

Abstract

Dihydrotestosterone synthesis in prostate cancer from adrenal DHEA/DHEA-sulfate requires enzymatic conversion in tumor tissues. 3β-hydroxysteroid dehydrogenase-1 is an absolutely necessary enzyme for such dihydrotestosterone synthesis and is encoded by the gene HSD3B1 which comes in 2 functional inherited forms described in 2013. The adrenal-permissive HSD3B1(1245C) allele allows for rapid dihydrotestosterone synthesis. The adrenal-restrictive HSD3B1(1245A) allele limits androgen synthesis. Studies from multiple cohorts show that adrenal-permissive allele inheritance confers worse outcomes and shorter survival after castration in low-volume prostate cancer and poor outcomes after abiraterone or enzalutamide treatment for castration-resistant prostate cancer. Here, we review the clinical data and implications.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32866512      PMCID: PMC7657962          DOI: 10.1016/j.urology.2020.08.028

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  43 in total

1.  Augmentation of T cell levels and responses induced by androgen deprivation.

Authors:  Anja C Roden; Michael T Moser; Samuel D Tri; Maria Mercader; Susan M Kuntz; Haidong Dong; Arthur A Hurwitz; David J McKean; Esteban Celis; Bradley C Leibovich; James P Allison; Eugene D Kwon
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

2.  Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.

Authors:  Rana R McKay; Huihui Ye; Wanling Xie; Rosina Lis; Carla Calagua; Zhenwei Zhang; Quoc-Dien Trinh; Steven L Chang; Lauren C Harshman; Ashley E Ross; Kenneth J Pienta; Daniel W Lin; William J Ellis; Bruce Montgomery; Peter Chang; Andrew A Wagner; Glenn J Bubley; Adam S Kibel; Mary-Ellen Taplin
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

3.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

Authors:  M Bolla; D Gonzalez; P Warde; J B Dubois; R O Mirimanoff; G Storme; J Bernier; A Kuten; C Sternberg; T Gil; L Collette; M Pierart
Journal:  N Engl J Med       Date:  1997-07-31       Impact factor: 91.245

4.  Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.

Authors:  I B Joseph; J B Nelson; S R Denmeade; J T Isaacs
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

5.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

6.  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

7.  Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.

Authors:  Jason W D Hearn; Wanling Xie; Mari Nakabayashi; Nima Almassi; Chad A Reichard; Mark Pomerantz; Philip W Kantoff; Nima Sharifi
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

8.  Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Authors:  Karim Fizazi; Neal Shore; Teuvo L Tammela; Albertas Ulys; Egils Vjaters; Sergey Polyakov; Mindaugas Jievaltas; Murilo Luz; Boris Alekseev; Iris Kuss; Christian Kappeler; Amir Snapir; Toni Sarapohja; Matthew R Smith
Journal:  N Engl J Med       Date:  2019-02-14       Impact factor: 176.079

Review 9.  CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.

Authors:  J E Ang; D Olmos; J S de Bono
Journal:  Br J Cancer       Date:  2009-02-17       Impact factor: 7.640

10.  HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.

Authors:  Jason W D Hearn; Christopher J Sweeney; Nima Almassi; Chad A Reichard; Chandana A Reddy; Hong Li; Brian Hobbs; David F Jarrard; Yu-Hui Chen; Robert Dreicer; Jorge A Garcia; Michael A Carducci; Robert S DiPaola; Nima Sharifi
Journal:  JAMA Oncol       Date:  2020-04-09       Impact factor: 31.777

View more
  9 in total

1.  Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.

Authors:  Elahe A Mostaghel; Brett T Marck; Orpheus Kolokythas; Felix Chew; Evan Y Yu; Michael T Schweizer; Heather H Cheng; Phillip W Kantoff; Steven P Balk; Mary-Ellen Taplin; Nima Sharifi; Alvin M Matsumoto; Peter S Nelson; R Bruce Montgomery
Journal:  Clin Cancer Res       Date:  2021-08-18       Impact factor: 12.531

2.  ASO Author Reflections: Inheritance of Adrenal Permissive HSD3B1 Genotype Negatively Impacts Outcomes in Hormone Receptor-Positive Postmenopausal Breast Cancer.

Authors:  Meghan R Flanagan; Nima Sharifi; Vijayakrishna K Gadi
Journal:  Ann Surg Oncol       Date:  2022-07-11       Impact factor: 4.339

3.  Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer.

Authors:  Meghan R Flanagan; David R Doody; Jenna Voutsinas; Qian Wu; Kalyan Banda; Nima Sharifi; Christopher I Li; Vijayakrishna K Gadi
Journal:  Ann Surg Oncol       Date:  2022-07-01       Impact factor: 4.339

4.  Hypoxia-Reoxygenation Couples 3βHSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer.

Authors:  Liang Qin; Yoon-Mi Chung; Michael Berk; Bryan Naelitz; Ziqi Zhu; Eric Klein; Abhishek A Chakraborty; Nima Sharifi
Journal:  Cancer Res       Date:  2022-07-05       Impact factor: 13.312

5.  SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species.

Authors:  Pascal Demange; Etienne Joly; Julien Marcoux; Yves Génisson; Remi Chauvin; Patrick R A Zanon; Dymytrii Listunov; Pauline Rullière; Cécile Barthes; Céline Noirot; Jean-Baptiste Izquierdo; Alexandrine Rozié; Karen Pradines; Romain Hee; Maria Vieira de Brito; Marlène Marcellin; Remy-Felix Serre; Olivier Bouchez; Odile Burlet-Schiltz; Maria Conceição Ferreira Oliveira; Stéphanie Ballereau; Vania Bernardes-Génisson; Valérie Maraval; Patrick Calsou; Stephan M Hacker; Sébastien Britton
Journal:  Elife       Date:  2022-05-10       Impact factor: 8.713

6.  Inheritance of a common androgen synthesis variant allele is associated with female COVID susceptibility in UK Biobank.

Authors:  Jeffrey M McManus; Navin Sabharwal; Peter Bazeley; Nima Sharifi
Journal:  Eur J Endocrinol       Date:  2022-05-12       Impact factor: 6.558

7.  Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.

Authors:  Zejie Mei; Tao Yang; Ying Liu; Yuanyuan Gao; Zemin Hou; Qian Zhuang; Dongyin He; Xuebin Zhang; Qilong Tan; Xuyou Zhu; Yingyi Qin; Xi Chen; Chengdang Xu; Cuidong Bian; Xinan Wang; Chenyang Wang; Denglong Wu; Shengsong Huang; Zhenfei Li
Journal:  Cell Rep Med       Date:  2022-04-20

Review 8.  Hormonal Therapy for Prostate Cancer.

Authors:  Kunal Desai; Jeffrey M McManus; Nima Sharifi
Journal:  Endocr Rev       Date:  2021-05-25       Impact factor: 19.871

9.  Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer.

Authors:  Megan L Kruse; Mona Patel; Jeffrey McManus; Yoon-Mi Chung; Xiuxiu Li; Wei Wei; Peter S Bazeley; Fumihiko Nakamura; Aimalie Hardaway; Erinn Downs; Sarat Chandarlapaty; Mathew Thomas; Halle Cf Moore; George T Budd; W H Wilson Tang; Stanley L Hazen; Aaron Bernstein; Serena Nik-Zainal; Jame Abraham; Nima Sharifi
Journal:  JCI Insight       Date:  2021-10-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.